O	0	9	Treatment
O	10	18	patterns
O	19	22	and
O	23	31	clinical
O	32	40	outcomes
O	41	46	among
O	47	55	patients
O	56	65	receiving
B-intervention	66	77	palbociclib
I-intervention	78	80	in
I-intervention	81	92	combination
I-intervention	93	97	with
I-intervention	98	100	an
I-intervention	101	110	aromatase
I-intervention	111	120	inhibitor
I-intervention	121	123	or
I-intervention	124	135	fulvestrant
O	136	139	for
O	140	142	HR
O	142	143	+
O	143	144	/
O	144	148	HER2
O	148	149	-
O	149	157	negative
O	158	166	advanced
O	166	167	/
O	167	177	metastatic
O	178	184	breast
O	185	191	cancer
O	192	194	in
O	195	199	real
O	199	200	-
O	200	205	world
O	206	214	settings
O	215	217	in
O	218	221	the
B-location	222	224	US
O	224	225	:
O	226	233	Results
O	234	238	from
O	239	242	the
O	243	247	IRIS
O	248	253	study
O	253	254	.

O	255	266	Palbociclib
O	267	269	is
O	270	271	a
O	272	281	selective
O	282	288	cyclin
O	288	289	-
O	289	298	dependent
O	299	305	kinase
O	306	307	(
O	307	310	CDK
O	310	311	)
O	312	313	4
O	313	314	/
O	314	315	6
O	316	325	inhibitor
O	326	334	approved
O	335	338	for
O	339	342	use
O	343	345	in
O	346	360	postmenopausal
O	361	366	women
O	367	371	with
O	372	379	hormone
O	380	388	receptor
O	388	389	-
O	389	397	positive
O	397	398	,
O	399	404	human
O	405	414	epidermal
O	415	421	growth
O	422	428	factor
O	429	430	2
O	430	431	-
O	431	439	negative
O	440	441	(
O	441	443	HR
O	443	444	+
O	444	445	/
O	445	449	HER2
O	449	450	-
O	450	451	)
O	452	460	advanced
O	460	461	/
O	461	471	metastatic
O	472	478	breast
O	479	485	cancer
O	486	487	(
O	487	490	ABC
O	490	491	/
O	491	494	MBC
O	494	495	)
O	495	496	.

O	497	508	Palbociclib
O	509	512	has
O	513	519	proven
O	520	528	benefits
O	529	531	in
O	532	537	phase
O	538	541	III
O	542	549	placebo
O	549	550	-
O	550	560	controlled
O	561	568	studies
O	568	569	;
O	570	577	however
O	577	578	,
O	579	583	real
O	583	584	-
O	584	589	world
O	590	597	outcome
O	598	602	data
O	603	606	are
O	607	614	lacking
O	614	615	.

O	616	619	The
O	620	627	Ibrance
O	628	632	Real
O	633	638	World
O	639	647	Insights
O	648	649	(
O	649	653	IRIS
O	653	654	)
O	655	660	study
O	661	670	evaluated
O	671	682	palbociclib
O	683	686	use
O	687	689	in
O	690	698	patients
O	699	703	with
O	704	706	HR
O	706	707	+
O	707	708	/
O	708	712	HER2
O	712	713	-
O	714	717	ABC
O	717	718	/
O	718	721	MBC
O	722	724	in
O	725	728	the
O	729	733	real
O	733	734	-
O	734	739	world
O	740	747	setting
O	748	750	in
O	751	754	the
O	755	757	US
O	757	758	,
O	759	768	Argentina
O	768	769	,
O	770	773	and
O	774	781	Germany
O	781	782	.

O	783	787	Here
O	788	790	we
O	791	799	describe
O	800	807	results
O	808	811	for
O	812	815	the
O	816	818	US
O	819	826	patient
O	827	835	subgroup
O	835	836	.

O	837	841	IRIS
O	842	845	was
O	846	847	a
O	848	861	retrospective
O	862	869	medical
O	870	875	chart
O	876	882	review
O	883	888	study
O	889	891	of
B-eligibility	892	900	patients
I-eligibility	901	905	with
I-eligibility	906	915	confirmed
I-eligibility	916	918	HR
I-eligibility	918	919	+
I-eligibility	919	920	/
I-eligibility	920	924	HER2
I-eligibility	924	925	-
I-eligibility	926	929	ABC
I-eligibility	929	930	/
I-eligibility	930	933	MBC
O	934	937	who
O	938	946	received
O	947	958	palbociclib
O	959	963	with
O	964	970	either
O	971	973	an
O	974	983	aromatase
O	984	993	inhibitor
O	994	995	(
O	995	997	AI
O	997	998	)
O	999	1001	as
O	1002	1009	initial
O	1010	1019	endocrine
O	1019	1020	-
O	1020	1025	based
O	1026	1033	therapy
O	1034	1036	in
O	1037	1051	postmenopausal
O	1052	1057	women
O	1058	1060	or
B-control	1061	1072	fulvestrant
I-control	1072	1073	-
I-control	1073	1078	based
I-control	1079	1086	therapy
O	1087	1089	in
O	1090	1095	women
O	1096	1100	with
O	1101	1108	disease
O	1109	1120	progression
O	1121	1130	following
O	1131	1140	endocrine
O	1141	1148	therapy
O	1148	1149	.

O	1150	1160	Physicians
O	1161	1170	extracted
O	1171	1175	data
O	1176	1180	from
O	1181	1188	patient
O	1189	1196	medical
O	1197	1204	records
O	1205	1208	for
O	1209	1210	â‰¤
O	1210	1212	16
O	1213	1223	sequential
O	1224	1232	patients
O	1233	1237	each
O	1237	1238	.

O	1239	1247	Outcomes
O	1248	1256	included
B-outcome-Measure	1257	1268	progression
I-outcome-Measure	1268	1269	-
I-outcome-Measure	1269	1273	free
O	1274	1277	and
B-outcome-Measure	1278	1286	survival
I-outcome-Measure	1287	1292	rates
O	1292	1293	.

O	1294	1301	Records
O	1302	1306	were
O	1307	1316	extracted
O	1317	1320	for
B-total-participants	1321	1324	652
O	1325	1333	patients
O	1333	1334	:
B-intervention-participants	1335	1338	360
O	1339	1340	(
O	1340	1342	55
O	1342	1343	.
O	1343	1344	2
O	1344	1345	%
O	1345	1346	)
O	1347	1354	treated
O	1355	1359	with
O	1360	1371	palbociclib
O	1372	1373	+
O	1374	1376	AI
O	1377	1380	and
B-control-participants	1381	1384	292
O	1385	1386	(
O	1386	1388	44
O	1388	1389	.
O	1389	1390	8
O	1390	1391	%
O	1391	1392	)
O	1393	1400	treated
O	1401	1405	with
O	1406	1417	palbociclib
O	1418	1419	+
O	1420	1431	fulvestrant
O	1431	1432	.

O	1433	1436	The
B-outcome	1437	1439	12
I-outcome	1439	1440	-
I-outcome	1440	1445	month
I-outcome	1446	1457	progression
I-outcome	1457	1458	-
I-outcome	1458	1462	free
I-outcome	1463	1467	rate
O	1468	1471	was
B-iv-bin-percent	1472	1474	84
I-iv-bin-percent	1474	1475	.
I-iv-bin-percent	1475	1476	1
I-iv-bin-percent	1476	1477	%
O	1478	1481	for
O	1482	1490	patients
O	1491	1498	treated
O	1499	1503	with
O	1504	1515	palbociclib
O	1516	1517	+
O	1518	1520	AI
O	1521	1524	and
B-cv-bin-percent	1525	1527	79
I-cv-bin-percent	1527	1528	.
I-cv-bin-percent	1528	1529	8
I-cv-bin-percent	1529	1530	%
O	1531	1534	for
O	1535	1540	those
O	1541	1548	treated
O	1549	1553	with
O	1554	1565	palbociclib
O	1566	1567	+
O	1568	1579	fulvestrant
O	1579	1580	;
B-outcome	1581	1583	12
I-outcome	1583	1584	-
I-outcome	1584	1589	month
I-outcome	1590	1598	survival
I-outcome	1599	1604	rates
O	1605	1609	were
B-iv-bin-percent	1610	1612	95
I-iv-bin-percent	1612	1613	.
I-iv-bin-percent	1613	1614	1
I-iv-bin-percent	1614	1615	%
O	1616	1619	for
O	1620	1631	palbociclib
O	1632	1633	+
O	1634	1636	AI
O	1637	1640	and
B-cv-bin-percent	1641	1643	87
I-cv-bin-percent	1643	1644	.
I-cv-bin-percent	1644	1645	9
I-cv-bin-percent	1645	1646	%
O	1647	1650	for
O	1651	1662	palbociclib
O	1663	1664	+
O	1665	1676	fulvestrant
O	1676	1677	.

O	1678	1680	In
O	1681	1685	this
O	1686	1691	first
O	1692	1696	real
O	1696	1697	-
O	1697	1702	world
O	1703	1713	assessment
O	1714	1716	of
O	1717	1725	clinical
O	1726	1734	outcomes
O	1735	1737	in
O	1738	1740	US
O	1741	1749	patients
O	1750	1754	with
O	1755	1757	HR
O	1757	1758	+
O	1758	1759	/
O	1759	1762	HER
O	1762	1763	-
O	1764	1767	ABC
O	1767	1768	/
O	1768	1771	MBC
O	1771	1772	,
O	1773	1782	treatment
O	1783	1787	with
O	1788	1799	palbociclib
O	1800	1802	in
O	1803	1814	combination
O	1815	1819	with
O	1820	1822	AI
O	1823	1825	or
O	1826	1837	fulvestrant
O	1838	1850	demonstrated
O	1851	1860	favorable
O	1861	1874	effectiveness
O	1875	1877	in
O	1878	1883	terms
O	1884	1886	of
O	1887	1898	progression
O	1898	1899	-
O	1899	1903	free
O	1904	1907	and
O	1908	1916	survival
O	1917	1922	rates
O	1922	1923	.

O	1924	1931	Ongoing
O	1932	1939	studies
O	1940	1943	are
O	1944	1950	needed
O	1951	1953	to
O	1954	1961	deliver
O	1962	1968	mature
O	1969	1977	clinical
O	1978	1985	outcome
O	1986	1990	data
O	1991	1997	beyond
O	1998	2000	12
O	2000	2001	/
O	2001	2003	24
O	2004	2010	months
O	2011	2013	in
O	2014	2017	the
O	2018	2022	real
O	2022	2023	-
O	2023	2028	world
O	2029	2036	setting
O	2036	2037	.
